Table of Contents
International Journal of Proteomics
Volume 2010, Article ID 964251, 9 pages
Research Article

Cladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders

1School of Molecular and Microbial Biosciences, University of Sydney, Sydney, NSW 2006, Australia
2Department of Haematology and Transfusion Medicine, Royal North Shore Hospital, St. Leonards, NSW 2065, Australia

Received 17 December 2009; Accepted 15 February 2010

Academic Editor: Peter Nilsson

Copyright © 2010 Carlos Cassano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The purine analogs, fludarabine nucleoside (FdA), and cladribine (CdA) (1  M, 24 hours), significantly changed the levels of some surface antigens on the human B-cell lines MEC2 and Raji. Changes in the surface proteins were identified using a Cluster of Differentiation (CD) antibody microarray that captures live cells and confirmed by flow cytometry. For Raji cells, CdA up-regulated CD10, CD54, CD80, and CD86, with repression of CD22, while FdA up-regulated CD20, CD54, CD80, CD86 and CD95. For MEC2 cells, CdA up-regulated CD11a, CD20, CD43, CD45, CD52, CD54, CD62L, CD80, CD86, and CD95, but FdA had no effect. Up-regulation of particular CD antigens induced on a B-cell lymphoproliferative disorder by a purine analog could provide targets for therapeutic antibodies with synergistic cell killing.